The U.S. government has ordered another 600,000 doses of sotrovimab, developed by GlaxoSmithKline and Vir Biotechnology. The drug is designed to treat COVID-19 at an early stage. The companies will deliver additional doses during Q1 2022. In total, GSK and Vir have signed agreements to supply approximately 1.7 million doses of sotrovimab worldwide.
The U.S. government has ordered another 600,000 doses of sotrovimab, developed by GlaxoSmithKline and Vir Biotechnology. The drug is designed to treat COVID-19 at an early stage. The companies will deliver additional doses during Q1 2022. In total, GSK and Vir have signed agreements to supply approximately 1.7 million doses of sotrovimab worldwide. 
investors.vir.bio
English (US) 